Alvotech Stock Price, News & Analysis

Alvotech (NASDAQ: ALVO) has signed an agreement with DNB Carnegie Investment Bank AB to provide liquidity services for its Swedish Depository Receipts (SDRs) trading on Nasdaq Stockholm. Starting May 20, 2025, DNB Carnegie will act as a liquidity provider, continuously quoting prices for Alvotech's SDRs in compliance with Nasdaq Stockholm's minimum requirements. The primary objective is to enhance SDR liquidity and minimize the spread between buying and selling prices.

Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has commenced trading on Nasdaq Stockholm on May 19, 2025. The company offered Swedish Depository Receipts (SDRs) at SEK 87.51 per SDR, which was multiple times oversubscribed with over 3,000 individual subscribers. The offering included 441,600 SDRs, generating gross proceeds of approximately SEK 39 million. Each SDR represents one ordinary share. This listing expands Alvotech's presence to three markets: Nasdaq Stockholm, Nasdaq Global Market (US), and Nasdaq Iceland Main Market. The move follows Alvotech's recent acquisition of Xbrane Biopharma's R&D operations at the Karolinska life-science hub in Sweden, expected to close in early June 2025. The company aims to strengthen its Nordic presence, improve capital access, and attract broader institutional and retail investors.

Alvotech (NASDAQ: ALVO) has announced the successful completion of its Swedish Depository Receipts (SDRs) offering for its Nasdaq Stockholm listing. The offering, which ran from May 9-16, 2025, was multiple times oversubscribed and attracted over 3,000 new shareholders. The final SDR price was set at SEK 87.51, representing a 10% discount to the volume-weighted average share price on Nasdaq Iceland. The offering included 441,600 SDRs, generating gross proceeds of approximately SEK 39 million. Trading on Nasdaq Stockholm will commence on May 19, 2025, under the ticker "ALVO SDB". The listing follows Alvotech's recent acquisition of Xbrane Biopharma's R&D operations at the Karolinska life-science hub in Sweden, aimed at expanding its R&D capabilities and accessing a broader talent pool in the Swedish life-science sector.

Alvotech (ALVO) reported that Richard Davies, Deputy Chairman of the Board of Directors, has acquired 19,988 shares at a price of $10.18 per share on May 14, 2025. The total transaction value amounts to approximately $203,477. The transaction was filed with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) as part of the required disclosure for transactions of managers and closely associated persons.

Alvogen Lux Holdings S.ár.l., Alvotech's (ALVO) second-largest shareholder, has acquired 210,000 shares at ISK 1,277.38 per share. The transaction was reported through a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF). Alvogen Lux Holdings' ownership structure consists of CVC (40%), Aztiq (30%), and Temasek (20%) as its largest shareholders.

Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has announced its participation in the BofA Securities Healthcare Conference 2025 in Las Vegas from May 13-15, 2025. The company's management team will conduct one-on-one meetings and participate in a fireside chat on May 14, 2025, from 11:40 am to 12:10 pm EDT. A live audio webcast of the chat will be available to the public through Alvotech's investor relations website, with a replay accessible for 90 days post-event.

Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, announced its participation in the BofA Securities Healthcare Conference 2025 in Las Vegas from May 13-15, 2025. The company's management team will conduct one-on-one meetings and participate in a fireside chat on May 14, 2025, at 11:40 am-12:10 pm EDT. The chat will be accessible via live audio webcast on Alvotech's investor relations website, with a replay available for 90 days post-event.

Alvotech (ALVO) announced that its Chairman and CEO, Robert Wessman, has acquired 320,000 shares of the company at a price of ISK 1,255 per share. The transaction was executed at market opening and has been reported to the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) in accordance with regulatory requirements.

Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has appointed Dr. Balaji V. Prasad as Chief Strategy Officer. Dr. Prasad brings 25 years of pharmaceutical industry experience, combining medical expertise with financial analysis background. He previously served as a director and equities analyst at Barclays, covering US specialty pharma. His credentials include an MD from Bangalore Medical College and an MBA from IIM Ahmedabad.

Prior roles include portfolio management at a Swiss asset management firm and leadership positions at Barclays and Goldman Sachs' India healthcare coverage. Chairman and CEO Róbert Wessman highlighted Dr. Prasad's deep understanding of Alvotech's business and product pipeline as key assets for the company's growth.